Investing.com9d agobearish
HSBC lifts Novartis, downgrades Amgen in biopharma catalyst reviewInvesting.com -- HSBC adjusted ratings and target prices across its biopharma coverage, citing "a lower sector additional risk premium" following a rally in the second quarter of 2026.